Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients

This study aimed to compare the effects of ω-3 fatty acids and fibrate treatment on plasma levels and activities of hemostatic risk factors on glucose and lipid metabolism in subjects with isolated hypertriglyceridemia. seventy-three subjects with elevated triglyceride levels were allocated into one of the following treatment options: bezafibrate (200 mg twice daily),ω-3 fatty acids (1 g twice daily) or placebo. plasma lipids,glucose homeostasis markers (fasting and 2-h post-glucose load plasma glucose levels and homa),as well as plasma levels/activities of fibrinogen,factor vii and pai-1 were determined at baseline,on the day of randomization,and after 4 and 12 weeks of the treatment. not only did bezafibrate improve plasma lipids,but it also increased glucose sensitivity and tended to reduce post-glucose loads of plasma glucose. except for the reduction in plasma triglycerides,ω-3 fatty acids produced no effect on the lipid profile and insulin sensitivity. both treatment options reduced,to similar extents,plasma levels of fibrinogen and pai-1 and factor vii coagulant activity. our study indicates that,although fibrates exhibit more-pronounced metabolic effects than do ω-3 fatty acids,both these treatment options are equipotent in producing a complex beneficial effect on hemostasis in isolated hypertriglyceridemic subjects. copyright © 2011 by institute of pharmacology polish academy of sciences.